Lisinopril 10 mg Tablets Recalled for Metal Fragment Contamination
RemedyRepack Inc. is recalling Lisinopril 10 mg prescription tablets due to a metal fragment embedded in one tablet. Affected lots were distributed to pharmacies in Pennsylvania and Alaska.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall involves a foreign object (metal fragment) in a prescription medication, which presents a risk of harm to patients who ingest it. No illnesses or injuries have been reported. Per the FDA severity rubric, a risk-of-harm product without reported injury is classified as High (3).
Plain-English summary
RemedyRepack Inc. is recalling specific lots of Lisinopril 10 mg prescription tablets due to the discovery of a metal fragment embedded in one tablet.
The recall affects 1,699 blister cards (30 tablets per card) with lot numbers J0636336-073022 and J0637605-080422, expiring 08/31/2023. The medication was distributed to two direct accounts in Pennsylvania and Alaska.
If you have received medication with these lot numbers, contact your healthcare provider or pharmacist immediately. Do not use tablets from the affected lots without first consulting your healthcare provider.
The recalled product
- Product
- Lisinopril 10 mg tablets, 30-count Blister Card, Rx Only, MFG: Lupin Pharma, Baltimore, MD Repackaged by: RemedyRepack Inc, Indiana PA. Original NDC# 68180-0980-03, Repackaged NDC# 70518-0468-00
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription
- Hazard
- foreign-material
- metal
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # J0636336-073022
- J0637605-080422
- Exp. date 08/31/2023
Distribution
Distributed in 2 states:
- AK
- PA
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27